Watch for the Anticoagulant Bevyxxa During Transitions of Care

March 2018

You may see some patients get Bevyxxa (beh-VYKE-sah, betrixaban), a new direct oral anticoagulant (DOAC), after hospital discharge.

It's not used the same way as other DOACs...Pradaxa (dabigatran), Xarelto (rivaroxaban), Eliquis (apixaban), or Savaysa (edoxaban).

Bevyxxa is only for "extended-duration" PREVENTION of venous thromboembolism (VTE) in certain hospitalized adults with multiple risk factors...such as reduced mobility plus older age and heart failure.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote